FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Boerse Frankfurt Warrants 15:43:02 2024-06-20 EDT | ||
| 7.72 EUR | -0.77% |
|
| Current month | -0.77% | ||
| 1 month | -1.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 24-06-20 | 7.74 | -0.51% |
| 24-06-19 | 7.78 | +0.39% |
| 24-06-18 | 7.75 | +0.52% |
| 24-06-17 | 7.71 | +0.65% |
| 24-06-14 | 7.66 | -1.67% |
Real-time Boerse Frankfurt Warrants
Last update June 20, 2024 at 03:43 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU9AU3 |
| ISIN | DE000SU9AU34 |
| Date issued | 2024-02-14 |
| Strike | 9,548 p |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.07 € |
|---|---|
| Lowest since issue | 7.53 € |
| Spread | 0.07 € |
| Spread % | 0.90% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.2
USD
Average target price
174.4
USD
Spread / Average Target
+11.00%
- Stock Market
- Certificates
- Certificat
